Vaccines: How to Use Market-Based Incentives to Ramp Up Production

Economic incentives to accelerate vaccine production would be much more productive than the empty threat of suing AstraZeneca - the additional cost for boosting vaccine supply for Europe might run into a couple of billions of euros, but this would be a lot less than the cost of prolonged disruption to the economy and society, let alone the lives lost. Clemens Fuest and Daniel Gros examine the EU's mistakes.